Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherBehavioral Pharmacology

BEHAVIOURAL CHARACTERIZATION OF THE NOVEL GAMMA-AMINOBUYTRIC ACID (B) (GABAB) RECEPTOR POSITIVE MODULATOR GS39783 (N, N'- DICYCLOPENTYL-2-METHYLSULFANYL-5-NITRO-PYRIMIDINE-4,6-DIAMINE): ANXIOLYTIC-LIKE ACTIVITY WITHOUT SIDE-EFFECTS ASSOCIATED WITH BACLOFEN OR BENZODIAZEPINES

John F. Cryan, Peter H Kelly, Frederique Chaperon, Conrad Gentsch, Cedric Mombereau, Kurt Lingenhoehl,, Wolfgang Froestl, Bernhard Bettler, Klemens Kaupmann and Will P.J.M Spooren
Journal of Pharmacology and Experimental Therapeutics April 27, 2004, DOI: https://doi.org/10.1124/jpet.104.066753
John F. Cryan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter H Kelly
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederique Chaperon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Conrad Gentsch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cedric Mombereau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kurt Lingenhoehl,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang Froestl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernhard Bettler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klemens Kaupmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Will P.J.M Spooren
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading
PDF extract preview

This is a PDF-only article. The first page of the PDF of this article appears above.

Next
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 387 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 387, Issue 1
1 Oct 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
BEHAVIOURAL CHARACTERIZATION OF THE NOVEL GAMMA-AMINOBUYTRIC ACID (B) (GABAB) RECEPTOR POSITIVE MODULATOR GS39783 (N, N'- DICYCLOPENTYL-2-METHYLSULFANYL-5-NITRO-PYRIMIDINE-4,6-DIAMINE): ANXIOLYTIC-LIKE ACTIVITY WITHOUT SIDE-EFFECTS ASSOCIATED WITH BACLOF…
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherBehavioral Pharmacology

BEHAVIOURAL CHARACTERIZATION OF THE NOVEL GAMMA-AMINOBUYTRIC ACID (B) (GABAB) RECEPTOR POSITIVE MODULATOR GS39783 (N, N'- DICYCLOPENTYL-2-METHYLSULFANYL-5-NITRO-PYRIMIDINE-4,6-DIAMINE): ANXIOLYTIC-LIKE ACTIVITY WITHOUT SIDE-EFFECTS ASSOCIATED WITH BACLOFEN OR BENZODIAZEPINES

John F. Cryan, Peter H Kelly, Frederique Chaperon, Conrad Gentsch, Cedric Mombereau, Kurt Lingenhoehl,, Wolfgang Froestl, Bernhard Bettler, Klemens Kaupmann and Will P.J.M Spooren
Journal of Pharmacology and Experimental Therapeutics April 27, 2004, DOI: https://doi.org/10.1124/jpet.104.066753

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherBehavioral Pharmacology

BEHAVIOURAL CHARACTERIZATION OF THE NOVEL GAMMA-AMINOBUYTRIC ACID (B) (GABAB) RECEPTOR POSITIVE MODULATOR GS39783 (N, N'- DICYCLOPENTYL-2-METHYLSULFANYL-5-NITRO-PYRIMIDINE-4,6-DIAMINE): ANXIOLYTIC-LIKE ACTIVITY WITHOUT SIDE-EFFECTS ASSOCIATED WITH BACLOFEN OR BENZODIAZEPINES

John F. Cryan, Peter H Kelly, Frederique Chaperon, Conrad Gentsch, Cedric Mombereau, Kurt Lingenhoehl,, Wolfgang Froestl, Bernhard Bettler, Klemens Kaupmann and Will P.J.M Spooren
Journal of Pharmacology and Experimental Therapeutics April 27, 2004, DOI: https://doi.org/10.1124/jpet.104.066753
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cromakalim Prodrugs are Analgesics in Chronic Pain Models
  • Chronic Naltrexone: Opioid-Seeking and Antinociception
  • Stimulus Effects of Nicotine Aerosol
Show more Behavioral Pharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics